Prostate cancer (PCa) is one of the most common cancers diagnosed in men in the world. The majority of patients develop resistant to androgen deprovation therapy, leading to castration-resistant PCa (CRPC). CRPC have a poorer prognosis and developing metastasis compared to hormone-sensitive PCa. To chracterize for new regulators of progression from HSPC to CRPC, LNCaP and C4-2 cells were selected as HSPC and CRPC, respectively. A comparative assessment of proein expression characteristics between two cells may provide insight into the regulatory landscape of CRPC.